A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EDG-15400 in Adults With Symptomatic Heart Failure With Preserved Ejection Fraction
Status: Recruiting
Location: See all (28) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 30
Maximum Age: 84
Healthy Volunteers: f
View:
• Males and nonpregnant females, ages ≥30 to \<85 years of age at screening
• Body weight ≥ 45 kg, BMI \< 40
• LVEF ≥ 50%
• Diagnosed with Heart Failure per American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) Guidelines for the Management of Heart Failure
• New York Heart Association (NYHA) functional class II or III
• If receiving Guideline-directed Medical Therapy, must be on stable doses
• Participants receiving a GLP-1 agonist prior to Screening must have no anticipated plans to change dose during the study
Locations
United States
Alabama
Local Institution - 1
RECRUITING
Birmingham
Arkansas
Local Institution - 25
NOT_YET_RECRUITING
Little Rock
California
Local Institution - 2
NOT_YET_RECRUITING
Beverly Hills
Local Institution - 3
NOT_YET_RECRUITING
San Diego
Local Institution - 4
RECRUITING
Vista
Florida
Local Institution - 24
NOT_YET_RECRUITING
Gainesville
Illinois
Local Institution - 5
RECRUITING
Peoria
Indiana
Local Institution - 26
NOT_YET_RECRUITING
Fort Wayne
Local Institution - 6
NOT_YET_RECRUITING
Indianapolis
Louisiana
Local Institution - 7
RECRUITING
Houma
Maryland
Local Institution - 8
NOT_YET_RECRUITING
Baltimore
Michigan
Local Institution - 9
NOT_YET_RECRUITING
Ypsilanti
Minnesota
Local Institution - 28
NOT_YET_RECRUITING
Minneapolis
Missouri
Local Institution - 11
NOT_YET_RECRUITING
Kansas City
Local Institution - 12
NOT_YET_RECRUITING
St Louis
Mississippi
Local Institution - 10
NOT_YET_RECRUITING
Jackson
North Carolina
Local Institution - 14
NOT_YET_RECRUITING
Greensboro
New York
Local Institution - 13
NOT_YET_RECRUITING
New York
Ohio
Local Institution - 15
NOT_YET_RECRUITING
Cincinnati
Oklahoma
Local Institution - 27
NOT_YET_RECRUITING
Tulsa
Pennsylvania
Local Institution - 16
NOT_YET_RECRUITING
Mechanicsburg
South Carolina
Local Institution - 17
NOT_YET_RECRUITING
Charleston
Texas
Local Institution - 18
NOT_YET_RECRUITING
Dallas
Local Institution - 19
NOT_YET_RECRUITING
Houston
Local Institution - 20
NOT_YET_RECRUITING
Houston
Local Institution - 21
NOT_YET_RECRUITING
Houston
Virginia
Local Institution - 22
NOT_YET_RECRUITING
Charlottesville
Washington
Local Institution - 23
NOT_YET_RECRUITING
Seattle
Contact Information
Primary
Study Director: Medical Director, Edgewise Therapeutics, Inc.